$31.41
0.732.38%
Last update: Oct 23, 4:41 PM
Pharvaris NV (PHVS) Stock Price, Quote, News & History
PHVSNASDAQ
Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.
You can purchase shares of Pharvaris (NASDAQ:PHVS) through any online brokerage.
Other companies in Pharvaris’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Pharvaris has a consensus price target of $51.22.
The stock price for Pharvaris (NASDAQ: PHVS) is $31.25 last updated October 23, 2026 at 4:41 PM EDT.
There are no upcoming dividends for Pharvaris.
Pharvaris does not have any upcoming earnings scheduled.
There is no upcoming split for Pharvaris.
Pharvaris is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules,...
